Global Antisense and RNAi Therapeutics Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Antisense and RNAi Therapeutics Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Antisense and RNAi Therapeutics Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Antisense and RNAi Therapeutics Drug market is projected to reach US$ 1250.2 million in 2029, increasing from US$ 852 million in 2022, with the CAGR of 6.3% during the period of 2024 to 2029. Demand from Neuromuscular Diseases and ATTR are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Antisense and RNAi Therapeutics Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Antisense and RNAi Therapeutics Drug key companies include Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics and Akcea Therapeutics, etc. Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals are top 3 players and held % share in total in 2022.
Antisense and RNAi Therapeutics Drug can be divided into Antisense Oligonucleotide, Aptamer and Other,, etc. Antisense Oligonucleotide is the mainstream product in the market, accounting for % share globally in 2022.
Antisense and RNAi Therapeutics Drug is widely used in various fields, such as Neuromuscular Diseases, ATTR, Hepatic VOD and Other, etc. Neuromuscular Diseases provides greatest supports to the Antisense and RNAi Therapeutics Drug industry development. In 2022, global % share of Antisense and RNAi Therapeutics Drug went into Neuromuscular Diseases filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antisense and RNAi Therapeutics Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Antisense and RNAi Therapeutics Drug market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Antisense and RNAi Therapeutics Drug introduction, etc. Antisense and RNAi Therapeutics Drug Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Antisense and RNAi Therapeutics Drug market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Antisense and RNAi Therapeutics Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Antisense and RNAi Therapeutics Drug market is projected to reach US$ 1250.2 million in 2029, increasing from US$ 852 million in 2022, with the CAGR of 6.3% during the period of 2024 to 2029. Demand from Neuromuscular Diseases and ATTR are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Antisense and RNAi Therapeutics Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Antisense and RNAi Therapeutics Drug key companies include Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics and Akcea Therapeutics, etc. Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals are top 3 players and held % share in total in 2022.
Antisense and RNAi Therapeutics Drug can be divided into Antisense Oligonucleotide, Aptamer and Other,, etc. Antisense Oligonucleotide is the mainstream product in the market, accounting for % share globally in 2022.
Antisense and RNAi Therapeutics Drug is widely used in various fields, such as Neuromuscular Diseases, ATTR, Hepatic VOD and Other, etc. Neuromuscular Diseases provides greatest supports to the Antisense and RNAi Therapeutics Drug industry development. In 2022, global % share of Antisense and RNAi Therapeutics Drug went into Neuromuscular Diseases filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antisense and RNAi Therapeutics Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Segment by Application
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Antisense and RNAi Therapeutics Drug market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Antisense and RNAi Therapeutics Drug introduction, etc. Antisense and RNAi Therapeutics Drug Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Antisense and RNAi Therapeutics Drug market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices